| MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T | Frank Vinluan | 08/03/20 | Europe |
| Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma | Frank Vinluan | 07/24/20 | San Francisco |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug | Sarah de Crescenzo | 06/15/20 | National |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| War Paint to Bone Paint: MIT Spinout Aims to Transform Regenerative Meds | Dan Stanton | 04/21/20 | Boston |
| Lantern Pharma IPO File Illuminates Plan to “Rescue” Failed Cancer Drugs | Frank Vinluan | 04/17/20 | Texas |
| UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug | Sarah de Crescenzo | 04/15/20 | New York |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Gilead Boosts Cancer Drug Pipeline With $4.9B Deal for Forty Seven | Frank Vinluan | 03/02/20 | San Francisco |
| United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial | Frank Vinluan | 02/03/20 | National |
| Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus | Frank Vinluan | 01/29/20 | Boston |
| Epizyme’s Soft Tissue Cancer Drug Granted Speedy FDA Approval | Frank Vinluan | 01/23/20 | Boston |
| Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug | Frank Vinluan | 01/13/20 | National |
| Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck | Frank Vinluan | 12/04/19 | San Francisco |
| Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3 | Frank Vinluan | 11/04/19 | San Diego |
| With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer | Frank Vinluan | 10/28/19 | New York |
| Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More | Frank Vinluan | 10/18/19 | National |
| Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test | Frank Vinluan | 10/16/19 | Indiana |
| Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street | Frank Vinluan | 10/03/19 | National |
| Dova Pharmaceuticals Agrees to Sobi Acquisition, Shares Jump 38% | Frank Vinluan | 09/30/19 | Raleigh Durham |
| Drug Pricing: Innovation, Investment, and the Public Good | Johannes Fruehauf | 09/24/19 | Boston |
| At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More | Ben Fidler | 09/09/19 | National |
| Merck Data Are Another Step for Immunotherapy in Breast Cancer | Ben Fidler | 07/29/19 | New York |
| Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck | Ben Fidler | 07/24/19 | New York |
| Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More | Frank Vinluan | 07/19/19 | National |
| Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More | Frank Vinluan | 06/21/19 | National |
| Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer | Sarah de Crescenzo | 06/19/19 | San Diego |
